INCR (Intercure) Other Stockholders Equity: $6.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCR Intercure Ltd INCR
67 GF Score
Price $5.34
GF Value $6.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intercure Other Stockholders Equity?

Intercure INCR -2.95% 67 Other Stockholders Equity is $6.51 Mil as of Dec. 2025. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Intercure's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $6.51 Mil.

Intercure's quarterly Other Stockholders Equity increased from Dec. 2024 ($0.00 Mil) to Jun. 2025 ($6.52 Mil) but then declined from Jun. 2025 ($6.52 Mil) to Dec. 2025 ($6.51 Mil).

Intercure's annual Other Stockholders Equity increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil) and increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($6.51 Mil).

Intercure Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Intercure's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intercure Other Stockholders Equity Chart

Intercure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.84 2.84 -0.00 0.00 6.51

Intercure Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 6.52 6.51
INCR
67GF Score
Intercure Ltd INCR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intercure Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $6.51 Mil mean?
Intercure (INCR) has a Other Stockholders Equity of $6.51 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Intercure and its competitors.
Is Intercure's Other Stockholders Equity too high?
Intercure's current Other Stockholders Equity is $6.51 Mil. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's Other Stockholders Equity compare to CTOR and ZYBT?
Intercure's Other Stockholders Equity of $6.51 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Intercure and its competitors. Intercure's current Other Stockholders Equity is $6.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.34 — trading 13.7% below its estimated fair value. The current Other Stockholders Equity is $6.51 Mil. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Intercure (INCR), the current Other Stockholders Equity is $6.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intercure (INCR) Overvalued in 2026?

Based on GuruFocus' analysis, Intercure stock appears to be undervalued. The current stock price of $5.34 is trading 13.7% below its estimated GF Value™ of $6.18. GuruFocus considers Intercure to be Modestly Undervalued.

Key valuation signals for INCR:

  • Other Stockholders Equity: $6.51 Mil
  • GF Value™: $6.18 vs. price of $5.34 (13.7% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intercure Business Description

Other Exchanges INCR:Israel
Address 85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score

Get the complete analysis for INCR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.34
Price
$6.18
GF Value